FDA Panel: Not Enough Data to OK ‘Abuse-Deterrent’ Opioid

Photo by frankieleon via Flickr

 

TRENTON, N.J. (AP) — A panel of Food and Drug Administration advisers voted against approving a new opioid painkiller with a unique feature for deterring abuse: It releases a deep-blue dye if someone tries to get high by crushing, chewing or snorting pills.

Panelists voted overwhelmingly against approving Intellipharmaceutics International’s generic version of extended-release Oxycontin, a key drug in the U.S. opioid addiction epidemic. The FDA usually follows its advisers’ advice.

Doctors and scientists raised many concerns about the dye’s safety for intended patients, and its effectiveness in deterring opioid abusers. Most said the company hadn’t done enough studies of the drug.

Some suggested blue stains around the mouth or nose from trying to abuse the drug could become popular among addicts. Others said the dye’s “Scarlet Letter” shaming approach was insensitive.

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts
Pill Press
Read More

DEA Cracks Down on Internet Pill Press Sales

For years now it has been incredibly easy to purchase tools online to use in the production of fake pills, designed to look like their pharmaceutical counterparts but typically containing fentanyl. The DEA is now attempting to curb the sale of such tools.
Total
0
Share